sj-docx-1-mdm-10.1177_0272989X241230071 – Supplemental material for A Tutorial on Net Benefit Regression for Real-World Cost-Effectiveness Analysis Using Censored Data from Randomized or Observational Studies

Supplemental material, sj-docx-1-mdm-10.1177_0272989X241230071 for A Tutorial on Net Benefit Regression for Real-World Cost-Effectiveness Analysis Using Censored Data from Randomized or Observational Studies by Shuai Chen, Heejung Bang and Jeffrey S. Hoch in Medical Decision Making</p

Hypothesis 1 at 14-day follow up.

<p>Hypothesis 1 at 14-day follow up.</p

Hypothesis 1 at six-month follow up.

<p>Hypothesis 1 at six-month follow up.</p

Number of adverse events in the total sample.

<p>Total N 180,333.</p

Kaplan-Meier failure curves for adverse events during 14-day follow-up after the first prescription of ibuprofen.

<p>GI; Gastrointestinal.</p

ICD-9-CM codes for severity of gastrointestinal adverse events.

<p>ICD-9-CM codes for severity of gastrointestinal adverse events.</p

Hypothesis 2 at six-month follow up.

<p>Hypothesis 2 at six-month follow up.</p

Kaplan-Meier failure curves for adverse events during six-month follow-up after the first prescription of ibuprofen.

<p>GI; Gastrointestinal.</p

Demographic description of the sample.

<p>SD; standard deviation, IQR; interquartile range.</p

Hypothesis 2 at six-month follow up.

<p>Hypothesis 2 at six-month follow up.</p